1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023

EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023

Summary

Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). DME is often a complication of diabetic retinopathy, and is the most common cause of vision loss in individuals with diabetes, especially if left untreated. The risk for ME is high in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population in the 7MM will increase by 34.2% during the forecast period, from 922,492 cases in 2013 to 1,238,301 cases in 2023. The total prevalent cases of ME following BRVO in the 7MM will increase by 13.7% during the forecast period, from 294,862 cases in 2013 to 335,346 cases in 2023. The total prevalent cases of ME following CRVO in the 7MM will increase by 19.6% during the forecast period, from 114,571 cases in 2013 to 136,973 cases in 2023.

GlobalData’s epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across markets.

Scope

- The Diabetic Macular Edema (DME) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for DME in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) segmented by sex and age (20-39 years, 40-59 years, 60-79 years, and =80 years) in these markets.
- The DME epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global DME market.
- Quantify patient populations in the global DME market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for DME therapeutics in each of the markets covered.
- Identify the number of ME cases following BRVO and CRVO.

Table Of Contents

EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023
1 Table of Contents
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 12
3.3.3 Japan 13
3.4 Forecast Methodology 13
3.4.1 Sources Used 15
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetes 18
3.4.4 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetic Retinopathy 21
3.4.5 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 22
3.4.6 Forecast Assumptions and Methods - Total Prevalent Cases of ME following BRVO and CRVO 23
3.5 Epidemiological Forecast for Macular Edema (2013-2023) 25
3.5.1 Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 25
3.5.2 Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 27
3.5.3 Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 29
3.5.4 Total Prevalent Cases of ME Following BRVO 31
3.5.5 Age-Specific Total Prevalent Cases of ME Following BRVO 33
3.5.6 Sex-Specific Total Prevalent Cases of ME following BRVO 35
3.5.7 Total Prevalent Cases of ME Following CRVO 37
3.5.8 Age-Specific Total Prevalent Cases of ME Following CRVO 39
3.5.9 Sex-Specific Total Prevalent Cases of ME Following CRVO 41
3.6 Discussion 43
3.6.1 Epidemiological Forecast Insight 43
3.6.2 Limitations of the Analysis 44
3.6.3 Strengths of the Analysis 45
4 Appendix 46
4.1 Bibliography 46
4.2 About the Authors 50
4.2.1 Epidemiologists 50
4.2.2 Reviewers 50
4.2.3 Acting Director of Epidemiology 52
4.2.4 Global Head of Healthcare 52
4.3 About GlobalData 53
4.4 About EpiCast 53
4.5 Disclaimer 53

1.1 List of Tables

Table 1: Risk Factors for DME 11
Table 2: Comorbidities for DME 11
Table 3: 7MM, Sources of Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population 14
Table 4: 7MM, Sources of Total Prevalence of ME following BRVO and CRVO 14
Table 5: 7MM, Sources Not Used in Epidemiological Analysis of DME 17
Table 6: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ?20 Years, Both Sexes, N, 2013-2023 26
Table 7: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, (Row %), 2013 28
Table 8: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ?20 Years, N (Row %), 2013 30
Table 9: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 32
Table 10: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, (Row %), 2013 34
Table 11: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ?20 Years, N (Row %), 2013 36
Table 12: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 38
Table 13: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, (Row %), 2013 40
Table 14: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ?20 Years, N (Row %), 2013 42

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ?20 Years, Both Sexes, N, 2013-2023 27
Figure 2: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, 2013 29
Figure 3: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ?20 Years, N, 2013 31
Figure 4: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 33
Figure 5: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, 2013 35
Figure 6: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ?20 Years, N, 2013 37
Figure 7: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 39
Figure 8: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, 2013 41
Figure 9: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ?20 Years, N, 2013 43

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetic foot ulcers (DFUs)- Market Insights, Epidemiology and Market Forecast-2023

Diabetic foot ulcers (DFUs)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Diabetic foot ulcers (DFUs) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Diabetic foot ulcers (DFUs) - Epidemiology Forecast To 2023

Diabetic foot ulcers (DFUs) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Diabetic foot ulcers (DFUs) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Diabetic foot ulcers (DFUs) in seven major markets (US, France, Germany, ...

Type 2 Diabetes Disease : Patent Overview (Last 5 years)

Type 2 Diabetes Disease : Patent Overview (Last 5 years)

  • $ 2000
  • Industry report
  • November 2016
  • by Mordor Intelligence LLP

The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.this is claimed in ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.